A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.
John G KuruvillaChristopher RushtonDiego R VillaMuhammad AslamAnca PricaNizar Abdel SamadStephane DoucetJill DudeboutIsabelle FleuryGraeme FraserJean-Francois LaroucheMona ShafeyPamela SkrabekTanya SkameneRyan D MorinMiguel AlcaideSusana Ben-NeriahDavid LeeChad WinchLois E ShepherdDavid W ScottMichael CrumpBingshu E ChenAnnette E HayPublished in: British journal of haematology (2024)
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.